Clinical trials generate unprecedented volumes of complex data across multiple systems, vendors, and sites. As regulatory expectations evolve under ICH E6(R3), sponsors are increasingly required to demonstrate continuous, traceable oversight of clinical trial data, not simply report outcomes at the end of a study.  Why manual, spreadsheet-based review workflows are increasingly difficult to sustain under modern oversight expectations How automation and AI enable faster, more proactive monitoring of clinical data How modern oversight platforms support ALCOA+ data integrity through traceable analytics, audit trails, and documented review workflows Practical strategies sponsors and CROs are using to operationalize ICH E6(R3) requirements How Signals Clinical™ supports earlier risk detection and inspection-ready oversight Download the whitepaper to learn how clinical teams can move from reactive data review to continuous, compliance-ready oversight without increasing operational burden. |
